ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0807

Baseline Coping Strategies as Predictors of Outcomes in Patients with Early-onset Rheumatoid Arthritis (RA)

Zafer Akman1, Gilles Boire2, Nathalie Carrier3, Sophie Roux4, Ariel Masetto2, Artur deBrum Fernandes5, Patrick Liang2, Patricia L Dobkin6 and Allard-Chamard Hugues7, 1Istanbul University Cerrahpasa, İstanbul, Turkey, 2Universite de Sherbrooke, Sherbrooke, QC, Canada, 3CIUSSS de l'Estrie - CHUS, Sherbrooke, QC, Canada, 4Université de Sherbrooke, Sherbrooke, QC, Canada, 5Universite De Sherbrooke, Fleurimont, QC, Canada, 6McGill University, Montréal, QC, Canada, 7Universit de Sherbrooke, Sherbrooke, QC, Canada

Meeting: ACR Convergence 2021

Keywords: CHIP, coping, Patient reported outcomes, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 7, 2021

Title: RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Patients recently diagnosed with RA employ various coping strategies. We aimed to describe these strategies over time and determine if specific strategies impacted patient outcomes.

Methods: Consecutive patients meeting the criteria for early RA identified at the Centre Hospitalier Universitaire de Sherbrooke(CHUS) self-administered the Coping with Health Injuries and Problems (CHIP) questionnaire at baseline and yearly follow-ups, up to 5 years. CHIP consists of 32 items with 4 subscales: Distraction, Palliative, Instrumental, Emotional, each containing 8 questions scored from 1 to 5. The scores (range 8-40) over time were examined by gender. Correlation between score and clinical variables at baseline were computed. Baseline scores were used to predict disease outcomes over time. The primary outcomes were: remission according to Simple Disease Activity Index (SDAI) and disability according to the Modified-Health Assessment Questionnaire (M-HAQ). CHIP scores were analyzed with the continuous scale and dichotomized according to the upper or lower third of the scale (≥30 or ≥18). P-values were calculated with linear mixed regression models for continuous outcomes or with generalized estimating equation for dichotomic outcomes.

Results: 482 patients were enrolled between August 2006 and October 2020 (61% female). Baseline mean scores (SD) were: 24.01 (6.46) for Distraction, 23.58 (6.07) for Palliative, 31.48 (5.35) for Instrumental and 25.10 (7.95) for Emotional.

For all subscales, females scored significantly higher than males and scores varied significantly over time (Figure 1). For Distraction and Palliative, scores declined faster in males than females, with significantly different slopes (interaction: gender*time).

At baseline, Emotional subscale was significantly correlated with depressive symptoms measured with Center for Epidemiological Studies-Depression (CES-D) (r=0.58) and with M-HAQ, fatigue, pain, disease activity according to the patient and the physician (r values between 0.20 to 0.33). Palliative subscale at baseline had significant correlations with the same variables, albeit weaker (r values 0.10 to 0.28) (Table 1).

For baseline Emotional subscale, subjects with a score of ≥18 had less SDAI remission over time (RR 95% CI: 0.62 (0.52-0.74), p< 0.001) and higher M-HAQ over time (RR: 3.61 (2.24-5.82), p< 0.001) (Table 2). For Palliative, the best cut-off for SDAI remission was lower third (RR: 0.58 (0.44-0.77), p< 0.001) and upper third for M-HAQ (RR: 2.26 (1.32-3.86), p< 0.001). For Instrumental, the mean baseline score was above the upper third cut-off (≥30); the best cut-off for both remission and M-HAQ was thus set higher at ≥35.

Conclusion: CHIP questionnaire describes coping styles when facing health challenges such as recent-onset RA. Coping strategies vary across gender, female having the highest scores at baseline and over time. When maladaptive coping strategies dominate (e.g., emotional) poor outcomes are encountered. Our results indicate that CHIP may be a novel predictor for RA outcomes. Analyzing whether coping strategies add to existing models to predict outcomes in early RA patients is warranted.

Figure 1. Evolution of CHIP subscales over the five years according to gender

Table 1. Correlation between CHIP subscales at baseline and clinicals variables at baseline

Table 2. Impact of baseline CHIP on outcomes over time


Disclosures: Z. Akman, None; G. Boire, Abbvie, 1, 6, 7, BMS, 6, 7, Janssen, 1, 5, 6, Eli Lilly, 1, 7, Amgen, 7, Novartis, 6, 7, Pfizer, 7, Sandoz, 6, 7, Viatris, 1, 6, Samsung Bioepis, 1; N. Carrier, None; S. Roux, Amgen, 6; A. Masetto, AbbVie, 2, 5, 6, BMS, 2, 5, 6, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, Sanofi, 2, 5, 6, UCB, 2, 5, 6, Eli Lilly, 2, 5, 6, Janssen, 2, 5, 6, Amgen, 5, Merck, 5, Teva, 5; A. deBrum Fernandes, None; P. Liang, Janssen, 1, 5, 6, Hoffman-La Roche, 5, Novartis, 1, 6, Abbvie, 1, 6, BMS, 1, 6, Amgen, 1, 6, Merk, 1, 6; P. Dobkin, None; A. Hugues, Pfizer, 1, 6, Neomed, 7, Daiichi Sankyo, 7, Abbvie, 1, 6, Xencor, 7, Sanofi, 1, 6, Novartis, 1, 6, Amgen, 1, 6, Hoffmann-La Roche, 1, 6, Eli Lilly, 1, 6, Janssen, 1, 5, 6.

To cite this abstract in AMA style:

Akman Z, Boire G, Carrier N, Roux S, Masetto A, deBrum Fernandes A, Liang P, Dobkin P, Hugues A. Baseline Coping Strategies as Predictors of Outcomes in Patients with Early-onset Rheumatoid Arthritis (RA) [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/baseline-coping-strategies-as-predictors-of-outcomes-in-patients-with-early-onset-rheumatoid-arthritis-ra/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/baseline-coping-strategies-as-predictors-of-outcomes-in-patients-with-early-onset-rheumatoid-arthritis-ra/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology